Biomarkers and Treatment Efficacy in pMMR Endometrial Cancer – ENGOT
ENGOT shared a post on LinkedIn about a paper by Els Van Nieuwenhuysen et al. published in Gynaecological Oncology:
“Suggested reading for the week: A new publication reports exploratory biomarker analyses from the ENGOT-en10/BGOG/GOG-3041/DUO-E Phase III trial in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer.
The study evaluated carboplatin/paclitaxel plus durvalumab followed by durvalumab with or without olaparib compared with carboplatin/paclitaxel alone. In the pMMR subpopulation, exploratory analyses showed a highly heterogeneous biomarker landscape, with frequent overlap between biomarkers and tumour histologies. Across multiple biomarker and histological subgroups, progression-free survival hazard ratios favoured both durvalumab-containing treatment arms compared with control, with the durvalumab plus olaparib arm favoured in most assessed subgroups.
For patients, these findings add to the evidence that carboplatin/paclitaxel plus durvalumab followed by durvalumab plus olaparib may help delay disease progression in pMMR endometrial cancer, a group in which tumours can be biologically diverse.
The trial was led by The GOG Foundation, Inc with the Belgian Gynaecological Oncology Group as the ENGOT lead group in cooperation with CEEGOG, GEICO – Spanish Gynaecological Cancer Research Group, HeCOG-Hellenic Cooperative Oncology Group, ISGO, NOGGO e.V., NSGO-CTU and PGOG
Prof. Els Van Nieuwenhuysen (BGOG,) has previously presented findings at ESGO 2025 and IGCS 2024. Watch the videos on our website.
Read the paper:
Learn more about the trial.”
Title: Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial
Authors: Shannon N. Westin, Kathleen Moore, Hye Sook Chon, Jessica Thomes Pepin, Erin A. Salinas, David Starks, Paul A. DiSilvestro, Brian Slomovitz, Elen Vettu, Fernando Gálvez-Montosa, Kofi Agyemang-Prempeh, Flora Zagouri, Jae-Weon Kim, Qinglei Gao, Fernando Contreras Mejia, Andreia Cristina De Melo, Tadaaki Nishikawa, Matthew Kowgier, Sonia Iyer, Ying Wang, Els Van Nieuwenhuysen
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jul 25, 2026, 10:56PMOS Can Affect Much More Than Periods or Fertility – PCOS Awareness Association
-
Jul 25, 2026, 10:42Asma Khalil: Recreational Drug Use During Pregnancy, What Every Expectant Mother Should Know!
-
Jul 25, 2026, 10:40Khalil Faaed: Are Complex Y Chromosome Rearrangements the Missing Link in Unexplained Male Infertility?
-
Jul 25, 2026, 10:38Sean Lauber: Does Transferring a Cleavage or Blastocyst Stage Embryo Affect the Chance of Having a Boy?
-
Jul 25, 2026, 10:33Rokaya Hachicho: The Hidden Cost of Excessive Laser Use During Trophectoderm Biopsy!
-
Jul 25, 2026, 10:31Join the ISUOG Webinar on Late-Evolving Fetal Anomalies – ISUOG
-
Jul 25, 2026, 10:29Waiting Before Clamping the Umbilical Cord Improves Neonatal Outcomes! – RCOG
-
Jul 25, 2026, 10:27Christopher Robinson: The Impact of Body Mass Index on Misoprostol Dosing for Labor Induction!
-
Jul 25, 2026, 10:26Heavy Menstrual Bleeding and Dysmenorrhea in Adolescents – IJGO